Current controversies in follicular lymphoma

Vikas Aurora*, Jane N. Winter

*Corresponding author for this work

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Follicular lymphoma (FL) is characterized by its responsiveness to initial therapy, a pattern of repeated relapses, and a tendency for histologic progression to a process resembling diffuse, large B-cell lymphoma. Treatment decisions are complicated by the many effective options now available including combinations of conventional chemotherapy and monoclonal antibody, radioimmunotherapy, new targeted agents, and autologous and allogeneic stem cell transplantation. For selected patients, "watch and wait" or involved field irradiation may still be the most appropriate strategy. When therapy is required, a combination of rituximab and conventional chemotherapy results in improved outcomes compared to chemotherapy alone. Radioimmunotherapy alone or in combination with chemotherapy is an attractive strategy for patients with relapsed disease and may prove to be appropriate first line therapy. The role of stem cell transplant in FL requires further investigation. Novel agents with varied mechanisms of action continue to be developed. Enrollment of patients into clinical trials designed to address the many unanswered questions in FL is essential to improving clinical outcomes.

Original languageEnglish (US)
Pages (from-to)179-200
Number of pages22
JournalBlood Reviews
Volume20
Issue number4
DOIs
StatePublished - Jul 1 2006

Keywords

  • FLIPI
  • Fludarabine
  • Follicular lymphoma
  • Hematopoietic stem cell transplant
  • Interferon
  • Non-Hodgkin's lymphoma
  • Radioimmunotherapy
  • Rituximab
  • Vaccination

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Current controversies in follicular lymphoma'. Together they form a unique fingerprint.

  • Cite this